MX2024001777A - Derivado de sulfonamida, metodo de preparacion y uso medico del mismo. - Google Patents

Derivado de sulfonamida, metodo de preparacion y uso medico del mismo.

Info

Publication number
MX2024001777A
MX2024001777A MX2024001777A MX2024001777A MX2024001777A MX 2024001777 A MX2024001777 A MX 2024001777A MX 2024001777 A MX2024001777 A MX 2024001777A MX 2024001777 A MX2024001777 A MX 2024001777A MX 2024001777 A MX2024001777 A MX 2024001777A
Authority
MX
Mexico
Prior art keywords
preparation
method therefor
medical use
sulfonamide derivative
sulfonamide
Prior art date
Application number
MX2024001777A
Other languages
English (en)
Inventor
Feng He
Weikang Tao
Xiaomin Zhang
Weimin Hu
Original Assignee
Jiangsu Hengrui Pharmaceuticals Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jiangsu Hengrui Pharmaceuticals Co Ltd filed Critical Jiangsu Hengrui Pharmaceuticals Co Ltd
Publication of MX2024001777A publication Critical patent/MX2024001777A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/424—Oxazoles condensed with heterocyclic ring systems, e.g. clavulanic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Se proporciona un derivado de sulfonamida representado por la fórmula general (I), un método de preparación del mismo, una composición farmacéutica que contiene dicho derivado y su uso como agente terapéutico, especialmente como inhibidor de la Lisina acetil transferasa (KAT), y su uso en la preparación de un medicamento para el tratamiento y/o prevención del cáncer. (ver Fórmula).
MX2024001777A 2021-08-10 2022-08-10 Derivado de sulfonamida, metodo de preparacion y uso medico del mismo. MX2024001777A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
CN202110913249 2021-08-10
CN202111142090 2021-09-28
CN202111500231 2021-12-09
PCT/CN2022/111395 WO2023016484A1 (zh) 2021-08-10 2022-08-10 磺酰胺衍生物、其制备方法及其在医药上的应用

Publications (1)

Publication Number Publication Date
MX2024001777A true MX2024001777A (es) 2024-02-29

Family

ID=85200573

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2024001777A MX2024001777A (es) 2021-08-10 2022-08-10 Derivado de sulfonamida, metodo de preparacion y uso medico del mismo.

Country Status (9)

Country Link
EP (1) EP4385989A1 (es)
JP (1) JP2024529068A (es)
KR (1) KR20240046530A (es)
CN (1) CN117597341A (es)
AU (1) AU2022325367A1 (es)
CA (1) CA3228411A1 (es)
MX (1) MX2024001777A (es)
TW (1) TW202321263A (es)
WO (1) WO2023016484A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20241355A1 (es) 2021-11-16 2024-07-03 Insilico Medicine Ip Ltd Inhibidores de lisina acetiltransferasa 6a (kat6a) y usos de los mismos
WO2023114710A1 (en) * 2021-12-13 2023-06-22 Aurigene Oncology Limited Fused benzoisoxazolyl compounds as kat6a inhibitors
WO2023192817A1 (en) 2022-03-28 2023-10-05 Isosterix, Inc. Inhibitors of the myst family of lysine acetyl transferases
WO2024165035A1 (zh) * 2023-02-10 2024-08-15 江苏恒瑞医药股份有限公司 一种磺酰胺衍生物结晶形式及其制备方法
WO2024201334A1 (en) * 2023-03-30 2024-10-03 Pfizer Inc. Kat6a as a predictive biomarker for treatment with a kat6a inhibitor and methods of treatment thereof

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE231505T1 (de) * 1991-03-28 2003-02-15 Eisai Co Ltd Neue heterocyclische/cyclische amine
US5750542A (en) * 1993-09-28 1998-05-12 Pfizer Benzisoxazole and benzisothizole derivatives as cholinesterase inhibitors
RU2350609C2 (ru) * 2002-02-22 2009-03-27 БАЙЕР ХелсКер ЛЛСи Производные бензофурана и бензотиофена, применяемые при лечении гиперпролиферативных заболеваний
CN101287493A (zh) * 2005-08-18 2008-10-15 根马布股份公司 采用cd4结合肽和辐射的疗法
GB201510019D0 (en) 2015-06-09 2015-07-22 Cancer Therapeutics Crc Pty Ltd Compounds
WO2017218960A1 (en) 2016-06-17 2017-12-21 Fronthera U.S. Pharmaceuticals Llc Hemoglobin modifier compounds and uses thereof
GB201713962D0 (en) 2017-08-31 2017-10-18 Ctxt Pty Ltd Compounds
US11685732B2 (en) 2017-11-29 2023-06-27 Epizyme, Inc. MYST family histone acetyltransferase inhibitors
GB201810092D0 (en) 2018-06-20 2018-08-08 Ctxt Pty Ltd Compounds
GB201810581D0 (en) 2018-06-28 2018-08-15 Ctxt Pty Ltd Compounds
CA3111649A1 (en) * 2018-09-07 2020-03-12 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Tricyclic compounds acting on crbn proteins
EA202092908A1 (ru) 2018-09-28 2021-05-14 Праксис Пресижн Медсинз, Инк. Модуляторы ионных каналов
CA3137472A1 (en) 2019-04-25 2020-10-29 Bayer Aktiengesellschaft Acyl sulfonamides for treating cancer
MD3986890T2 (ro) 2019-06-18 2024-04-30 Pfizer Derivați de benzizoxazolsulfonamide
US20220251075A1 (en) 2019-06-19 2022-08-11 Pfizer Inc. Cycloalkyl and Heterocycloalkyl Benzisoxazole Sulfonamide Derivatives

Also Published As

Publication number Publication date
WO2023016484A1 (zh) 2023-02-16
JP2024529068A (ja) 2024-08-01
CA3228411A1 (en) 2023-02-16
KR20240046530A (ko) 2024-04-09
AU2022325367A1 (en) 2024-02-08
TW202321263A (zh) 2023-06-01
EP4385989A1 (en) 2024-06-19
CN117597341A (zh) 2024-02-23

Similar Documents

Publication Publication Date Title
MX2024001777A (es) Derivado de sulfonamida, metodo de preparacion y uso medico del mismo.
MX2021007970A (es) Derivado de 6-oxo-1,6-dihidropiridazina, metodo de preparacion del mismo y uso medico del mismo.
MY196455A (en) Nitrile-Containing Compounds Useful as Antiviral Agents for The Treatment of a Coronavirus Infection
MX2021006421A (es) Anilidas de aminoácidos como moduladores de moléculas pequeñas de interleucinas-17 (il-17).
CR20210563A (es) Compuestos y métodos para el tratamiento de covid-19
BR112022000019A2 (pt) Composto da fórmula, composição farmacêutica e método de tratamento de câncer
PH12021551256A1 (en) Pantetheine derivatives and uses thereof
MX2023007853A (es) Compuesto heterociclico puenteado que contiene nitrogeno, metodo de preparacion y uso medico del mismo.
GEP20053595B (en) Cyclopentanoindoles, Compositions Containing Such Compounds and Methods of Treatment
MX2023003627A (es) Derivados de 1,2,3,4-tetrahidroquinolina como inhibidores de la activacion de yap/taz-tead para el tratamiento del cancer.
MX2023000314A (es) Formulaciones farmaceuticas transdermicas de cannabinoides.
MX2022005985A (es) Derivado de pirazolo-heteroarilo, metodo de preparacion y uso medico del mismo.
NZ598489A (en) Combination therapy for treating proliferative diseases
MX2022015554A (es) Moduladores de molecula peque?a de interleucina 17 (il-17).
BR112023022496A2 (pt) Composto heterocíclico contendo nitrogênio, método de preparação do mesmo, e aplicação do mesmo em medicamentos
MX2024000274A (es) Terapia combinada para el tratamiento de enfermedades del higado.
MX2021006724A (es) Compuestos de halo-alilamina y uso de los mismos.
MX2024004846A (es) Compuesto tetraciclico que contiene nitrogeno, metodo de preparacion del mismo y uso medico del mismo.
MX2023003576A (es) Compuesto como inhibidor de la akt cinasa.
MX2024000807A (es) Inhibidor de aak1 y uso de este.
BR112021017957A2 (pt) Derivado tienoeterocíclico, método de preparação do mesmo e uso médico do mesmo
BRPI1008000A2 (pt) composto, hidrobrometo, hidrocloreto, metanossulfonato, etano-1, 2-dissulfonato, inibidor de hsp90, agente para inibir a atividade de atpase de hsp90, agente para inibir a ligação de hsp90 em atp, medicamento, agente anticâncer, composição farmacêutica, método para tratar câncer, e, uso de um composto.
MX2023000868A (es) Derivado de isoindolina que contiene azufre, metodo de preparacion y uso medico del mismo.
MX2022003845A (es) Tratamientos cognitivos medicinales.
MX2023011814A (es) Derivados heterociclicos, composiciones farmaceuticas y su uso en el tratamiento o la mejora del cancer.